Key result
Catheter ablation linked to ~78% greater freedom from AF at six months versus AAT.
Why the study?
The study was conducted to evaluate the efficacy of catheter ablation of AF and its effect on the course of CHF compared with antiarrhythmic therapy in patients with left ventricular systolic dysfunction.
Does catheter ablation improve freedom from atrial fibrillation and heart failure parameters compared to antiarrhythmic therapy in patients with AF and LVEF <50%?
Cohort (n=80)
Does catheter ablation improve freedom from atrial fibrillation and heart failure parameters compared to antiarrhythmic therapy in patients with AF and LVEF <50%?
Absolute Event Rate: 80% vs 45%
p-value: p=0.001
Catheter ablation is more effective than antiarrhythmic therapy in maintaining sinus rhythm and improving left ventricular function, exercise tolerance, and quality of life in patients with atrial fibrillation and left ventricular systolic dysfunction.
May support ablation preference for rhythm control in AF with reduced EF; leaves open effects on HF outcomes pending RCTs.
Aim. To evaluate the efficacy of catheter ablation (CA) of atrial fibrillation (AF) in patients with left ventricular systolic dysfunction and the effect of the procedure on the course of chronic heart failure (CHF) compared with the use of antiarrhythmic therapy (AAT). Materials and methods. The study included patients (n=80) with left ventricular ejection fraction (LVEF) less than 50% and AF, who were divided into 2 groups: the first group (n=40) underwent CA, the second group included patients on AAT. At baseline and after 6 months of follow-up, transthoracic echocardiography, determination of NT-proBNP concentration, 6-minute walk test and The Minnesota Living With Heart Failure Questionnaire were performed. Results. After 6 months of follow-up, the absence of documented AF paroxysms was observed in 80% in the CA group versus 45% in the AAT group (p=0,001). A significant increase in LV EF was revealed in both groups, however, in CA group it was more significant (57% [50,5; 60] in the CA group versus 46% [40; 50] in the AAT group (p=0,0001)). There was a decrease in the left ventricle ESD and the left atrial size and volume in the CA group, while in the AAT group the dynamics of these parameters did not change within six months (p=0.0001). An improvement in the clinical course of CHF was observed in both groups: the level of NT-proBNP was 196,6 [116,5; 327,1] pg/ml and 540.5 [382,8; 861,2] pg/ml (0,0001), the 6-minute walk distance increased to 470 m [400; 500] and 368 [330; 400] m (p=0,0001), respectively, the improvement of the functional class (1,15±0,67 and 2,05±0,55 (p=0,0001)) and the quality of life (p=0,0001) were observed. Conclusion . CA is an effective method for patients with AF and CHF. The use of CA in patients with CHF promotes reverse remodeling, a decrease in the level of NT-proBNP, as well as an improvement in the quality of life and an increase in exercise tolerance.
No takes yet. Share an insight, caveat, or question.
Ardus et al. (2023) conducted a cohort in Atrial fibrillation and left ventricular systolic dysfunction (n=80). Catheter ablation vs. Antiarrhythmic therapy was evaluated on Absence of documented AF paroxysms (p=0.001). Catheter ablation resulted in a higher rate of absence of documented atrial fibrillation paroxysms compared to antiarrhythmic therapy (80% vs 45%, P=0.001) at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: